Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt
Executive Summary
Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.
You may also be interested in...
Independence Arrives For Bausch + Lomb Through IPO Priced Lower Than Forecast
Bausch Health shopped Bausch + Lomb IPO at share price between $21 and $24. In trading of nearly 14.4m shares on New York exchange, Bausch + Lomb’s share price stayed above opening $18.50 and reached $20.07 before closing at $20, up 11.11%.
Preparing For Expansion: Perrigo Sets $500M Private Offering, Bausch + Lomb IPO Details Filed
Perrigo intends to use net proceeds from $500m private offering along with cash on hand and funds from previous credit facilities to finance acquisition of HRA Pharma. Bausch Health reduces debt by $200m as it prepares to target proceeds from planned Bausch + Lomb IPO also to paying down debt.
Bausch Health’s 2022 Growth Led By Business With Separation Coming As Soon As One Month
Canadian firm reports Bausch + Lomb full-year and fourth-quarter revenue growth earnings as preparations continue to divest the business. Consumer health led Bausch + Lomb’s segments.